Choosing a biomanufacturing service organization: from the BSO perspective
Cell & Gene Therapy Insights 2026; 12(2), 203–213
DOI: 10.18609/cgti.2026.028
The wrong manufacturing partner costs more than time. A first-hand framework from the BSO side of the table — what sponsors must prepare, what a well-structured manufacturing partnership looks like, and where most projects go wrong before they even start.
How to prepare a project before approaching a BSO, and why under-prepared sponsors hit costly, repeated delays
The 7 key selection criteria, with real-world manufacturing case studies illustrating each one
What a fully integrated BSO offers that a conventional CDMO model cannot replicate
Under-prepared projects face recurring deviations and extended timelines. A full sponsor readiness checklist is included, covering documentation, materials, QMS maturity, and starting material strategy
A BSO with direct control over starting materials reduces variability at source, an outcome demonstrated through a real leukopak case study that is impossible to replicate in a siloed CDMO model
Integrated analytics co-developed with the process rather than added after the fact is the difference between regulatory readiness and costly late-stage redesigns